Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro

Su, W.P. Daniel; Sun, Lina; Yang, Shaodong; Hu, Zhao; Zeng, Taidui; Wu, Wei; Wang, Dong

doi:10.1002/jbt.22158

Cited by 34 publications

(35 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expressions of APOC1 mRNA and protein were upregulated in prostate tissue and the levels of APOC1 were increased in the serum of prostate adenocarcinoma patients (15). The mRNA and protein levels of APOC1 were also highly expressed in late stage lung cancer tissues, whereas no prognostic value of APOC1 could be identified in serum samples of lung cancer (16).…”

Section: Introductionmentioning

confidence: 96%

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer

Ren

et al. 2019

Ann. Transl. Med.

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is a common malignant cancer in the worldwide, especially in China. Patients with GC have poor prognosis, which is mainly due to lack of early diagnosis. Up to now, there is no good biomarker to detect GC at early stage. Apolipoprotein C1 (APOC1), a component of both triglyceriderich lipoproteins and high-density lipoproteins, is reported to be involved in numerous biological processes. Methods: Expression of APOC1 mRNA was analyzed by in silicon assay. Concentration of APOC1 in serum was measured by ELISA assay. Expression of APOC1 protein in GC tissue array was checked by immunohistochemistry. Results: It was firstly found that concentration of APOC1 in serum was significantly higher in GC than that in control. Expression of APOC1 protein was also higher in GC than that in adjacent issues of GC and normal tissues using tissues array by immunohistochemistry. In addition, the expression of APOC1 is significantly associated with clinical stage (P=0.011), tumor classification (P=0.010), as well as with the lymph node metastasis (P=0.048). Area under the curve (AUC) of receiver operating characteristic (ROC) curve of APOC1 was 0.803. Furthermore, elevated APOC1 expression in GC was found to be correlated with decreased overall survival (P=0.00214). Conclusions: All these results suggested that APOC1 might be a potential serum biomarker to diagnose GC and a potential prognostic marker for GC.

show abstract

Section: Introductionmentioning

confidence: 96%

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer

Ren

et al. 2019

Ann. Transl. Med.

View full text Add to dashboard Cite

show abstract

“…Through literature review, APOC1 has been identi ed as a promising serum marker for human cancers, which is conductive to cancer diagnosis and treatment [17][18][19][20][21]. Su et al [22] pointed out that APOC1 mediates cell survival, cell cycle distribution and apoptosis of prostate cancer via activating the surviving/Rb/p21/caspase-3 signaling. Ren et al [9] uncovered that upregulated APOC1 in colorectal carcinoma predicts a poor prognosis.…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling

jiang

Tang

Xue

et al. 2020

Preprint

View full text Add to dashboard Cite

Background RCC is a clinically common tumor in the urinary system, showing an upward trend of both incidence and mortality. APOC1 has been identified as a vital regulator in tumor progression. This study aims to uncover the biological function of APOC1 in RCC process and the underlying mechanism. Methods Differential levels of APOC1 in RCC samples and controls in a downloaded TCGA profile and clinical samples collected in our center were detected by qRT-PCR. The prognostic value of APOC1 in RCC was assessed by depicting Kaplan-Meier survival curves. After transfection of sh-APOC1 or oe-APOC1, cell phenotypes were examined through CCK-8, colony formation, Transwell assay and flow cytometry. Subsequently, EMT-related genes influenced by APOC1 were determined by Western blot. The involvement of Wnt3a in APOC1-regulated malignant process of RCC was then examined through a series of rescue experiments. Finally, a xenograft model was generated in nude mice for clarifying the in vivo function of APOC1 in RCC process. Results APOC1 was upregulated in RCC samples. Notably, its level was correlated to overall survival of RCC patients, displaying a certain prognostic value. APOC1 was able to stimulate proliferative and metastatic abilities in RCC cells. Wnt3a signaling was identified to be involved in APOC1-mediated RCC process. Notably, Wnt3a was able to reverse the regulatory effects of APOC1 on RCC cell phenotypes. In vivo knockdown of APOC1 slowed down the growth of RCC. Conclusions APOC1 stimulates the malignant process of RCC via targeting the Wnt3a signaling.

show abstract

“…The expression levels of ApoC-I, TTR and ApoC-III in the serum of patients with gastric cancer at clinical III/IV stage, lymph node metastasis and high/medium differentiation were higher than those with poorly differentiated gastric cancer at clinical I/II stage and without lymph node metastasis. On the one hand, APOC-I can mediate the proliferation and apoptosis of the cancer cells and regulate the cell cycle by controlling the signal pathways for Survivin, p21 and caspase-3 (27). On the other hand, as important regulators of lipoprotein metabolism in humans, ApoC-I and ApoC-III can delay the clearance of triglycerides in many aspects: ApoC-I can inhibit the binding of lipoproteins to LDL receptors to directly interfere with the uptake of fatty acids; ApoC-III inhibits fat degradation by interfering with the binding of lipoproteins to glycosaminoglycan on the cell surface (28).…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer

Wang

Jiang

2019

Oncol Lett

View full text Add to dashboard Cite

Diagnostic value of apolipoprotein C-I (ApoC-I), transthyretin (TTR) and ApoC-III in gastric cancer were evaluated. Retrospective analysis methods were used to collect 60 patients with gastric cancer first diagnosed in The First Affiliated Hospital of Jiaxing University. There were 60 patients with chronic atrophic gastritis in the benign lesion group and 60 healthy individuals in the control group. The expression levels of serum ApoC-I, TTR and ApoC-III was detected by enzyme-linked immunosorbent assay. Differences existed in the expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group, benign lesion group and control group (P<0.001), with the expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group being lower than that of the benign lesion group (P<0.05), and the expression levels of ApoC-I, TTR and ApoC-III in the benign lesion group being lower than that of the control group (P<0.05). The expression levels of ApoC-I, TTR and ApoC-III in the gastric cancer group were to a certain degree correlated with the clinical stage, lymph node metastasis and differentiation of patients in the gastric cancer group (P<0.05). The specificity and negative predictive value of combined detection were proven to be higher than the separate detection of the three factors (P<0.05). The detection of serum ApoC-I, TTR and ApoC-III was of great significance in the diagnosis of gastric cancer and the estimation of its severity. The method of combined detection is worth a further in-depth study as it could improve the specificity of diagnosis and have a higher negative predictive value.

show abstract

Apolipoprotein C1 promotes prostate cancer cell proliferation in vitro

Cited by 34 publications

References 39 publications

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer

Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer

Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling

Diagnostic value of apolipoprotein C-I, transthyretin and apolipoprotein C-III in gastric cancer

Contact Info

Product

Resources

About